# insitro

> insitro is a machine-learning-driven drug discovery and development company that uses high-content human data, cellular models and AI to find better targets and design better medicines. Founded in 2018 by Daphne Koller, the company runs its own therapeutic pipeline and partners with large pharma on programs in ALS, metabolic disease and oncology.

- **Founded:** 2018
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Daphne Koller (Founder & CEO)
- **Team size:** ~260
- **Products:** Virtual Human platform, TherML platform, Therapeutic pipeline
- **Notable:** Raised $643M+ in total funding by 2021, Built one of the largest in-house biological data generation operations in techbio, Three pharma collaborations producing nominated clinical targets

## Products & services

- **Virtual Human platform** — A genetically anchored causal AI engine that integrates in vitro cellular data with human clinical data to identify therapeutic targets and patient subgroups.
- **TherML platform** — AI platform used to design and optimize drug candidates against targets surfaced by Virtual Human.
- **Therapeutic pipeline** — Internal programs and partnered programs across ALS, metabolic disease (including NASH/MASH) and oncology.

## Achievements

- Raised $643M+ in total funding by 2021
- Built one of the largest in-house biological data generation operations in techbio
- Three pharma collaborations producing nominated clinical targets
- Named to multiple 'top AI/biotech' industry lists

## Latest updates

- **2026-03** — Bristol Myers Squibb nominated two additional ALS targets (ALS-2, ALS-3) from insitro's Virtual Human platform.
- **2024-12** — BMS nominated first ALS target (ALS-1) from the insitro collaboration.
- **2021-03** — Closed $400M Series C led by Canada Pension Plan Investment Board.

## Links

- Website: https://insitro.com
- LinkedIn: https://www.linkedin.com/company/insitro
- Twitter/X: https://twitter.com/insitro

---

Profile page: https://yespress.io/insitro
Published by YesPress — https://yespress.io
Last updated: 2026-05-19